The said patients are being recruited by Moffitt for the phase II study of the oral medication AZD6244 — an experimental anti-cancer drug that may stop the growth of cancer cells and is designed to block the pathway of a protein called MEK (important for cell survival).

According to Dr. Chris R. Garrett, principal investigator with Moffitt’s Gastrointestinal Oncology program:

“There’s no cure for advanced liver cancer that’s not amenable to surgery. We’re looking for a novel therapy to improve the outcome for patients with the disease.”

The said trial – also being conducted at Emory University, The University of North Carolina at Chapel Hill, Vanderbilt University and VCU Massey Cancer Center – is sponsored by The National Cancer Institute.

If you qualify as a participant or you someone who does, you can call clinical research nurse Tiffany Campos at (813) 745-8358.

Source: Moffitt Cancer Center

Post from: Blisstree

Participants to Advanced Liver Cancer Study, Wanted by Moffitt